About Alexis Bio
Alexis Bio is a company based in Boston (United States) founded in 2016 by Jon Adkins, Krysta Moulton, and Paul Holzer. Alexis Bio has raised $1.33 million across 1 funding round. The company has 3 employees as of December 31, 2022. Alexis Bio has completed 2 acquisitions, including ESSA Pharma and Repare Therapeutics. Alexis Bio offers products and services including Genetically Optimized Cells and Donor Tissues and Organs. Alexis Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Boston, United States
- Employees 3 as on 31 Dec, 2022
- Founders Jon Adkins, Krysta Moulton, Paul Holzer
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Xenotherapeutics Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$1.33 M (USD)
in 1 rounds
-
Latest Funding Round
$1.33 M (USD), Seed
Apr 06, 2021
-
Investors
-
Employee Count
3
as on Dec 31, 2022
-
Investments & Acquisitions
ESSA Pharma
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alexis Bio
Alexis Bio offers a comprehensive portfolio of products and services, including Genetically Optimized Cells and Donor Tissues and Organs.
Engineered animal cells to replace human cells for healing and function restoration.
Genetically altered materials for clinical replacement of damaged body parts.
Funding Insights of Alexis Bio
Alexis Bio has successfully raised a total of $1.33M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.33 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $1.3M
-
First Round
First Round
(06 Apr 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2021 | Amount | Seed - Alexis Bio | Valuation |
investors |
|
Investments & Acquisitions by Alexis Bio
Alexis Bio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include ESSA Pharma and Repare Therapeutics.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Targeted cancer therapies for genetic tumor alterations are developed.
|
2016 | ||||
|
Small molecule drugs for cancer treatment are developed.
|
2009 |
Financial Statements - Alexis Bio
Alexis Bio Comparisons
Competitors of Alexis Bio
Alexis Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| domain | founded_year | HQ Location |
Developer of drugs for treating rare and autoimmune diseases
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
Frequently Asked Questions about Alexis Bio
Alexis Bio was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Alexis Bio is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Paul Holzer is the current CEO of Alexis Bio. They have also founded this company.
Alexis Bio is a funded company, having raised a total of $1.33M across 1 funding round to date. The company's 1st funding round was a Seed of $1.33M, raised on Apr 06, 2021.
As of Dec 31, 2022, the latest employee count at Alexis Bio is 3.
Alexis Bio was founded in 2016 and is based in Boston, United States. Multipotent stem cell-based therapies are developed by the company for neurodegenerative diseases, infectious diseases, and skin and wound care. Lead candidates include Xeno-Skin, a live biotherapeutic skin xenotransplant for severe burns, and AB001 for Parkinsons disease. Operations focus on advancing these treatments in the biotechnology sector.
Alexis Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Alexis Bio offers Genetically Optimized Cells and Donor Tissues and Organs.
Alexis Bio has made 2 acquisitions, including ESSA Pharma, and Repare Therapeutics.